Center for Blood Oxygen Transport and Hemostasis
Baltimore, Maryland, 21201, United States
Location status: Recruiting
Location contact
Paul W Buehler, PhD
CONTACT
Tobi Rowden, RN
CONTACT
NCT Number: NCT05189262
Studying the dynamics of red blood cell lysis, pfH, protective proteins and organ injury, limits will be set for safe levels of pfH following the use of CPB. These results will be compared to existing laboratory-based methods for determining red blood cell damage to predict CPB assist device safety. Further, results from the studies described in this proposal will help develop therapeutic strategies to benefit patients by early detection of pfH and clearance protein levels that occur during CPB.
Interested in participating?
Request Info18 year–88 year
All sexes
Observational
Baltimore, Maryland, 21201, United States
Location status: Recruiting
Paul W Buehler, PhD
CONTACT
Tobi Rowden, RN
CONTACT
Cost estimates for brain, lung, cardiac, and kidney complications following complex cardiac surgeries that require a medical assist device to by-pass the heart and lungs (cardiopulmonary bypass, CPB) is estimated to cost $80 million per individual states in the US over a ten-year period. These extra costs represent a significant burden on the healthcare system but could be reduced by understanding how medical assist devices lead to organ injury associated with complex cardiac surgeries. The primary goals of this research are to (1) understand how hemoglobin released into plasma (pfH) from damaged red blood cells that passage through CPB contributes to organ injury. (2) Determine the amount of pfH necessary to cause organ injury. (3) Determine the concentration changes in protective proteins (called haptoglobin, hemopexin and transferrin) that remove pfH and its degradation products from the circulation. (4) Design a computer-based model that will determine the levels of pfH and protective proteins to predict the potential for organ injury. By studying the dynamics of red blood cell lysis, pfH, protective proteins and organ injury limits will be set for safe levels of pfH following the use of CPB. These results will be compared to existing laboratory-based methods for determining red blood cell damage to predict CPB assist device safety. Further, results from the studies described in this proposal will help develop therapeutic strategies to benefit patients by early detection of pfH and clearance protein levels that occur during CPB. The primary goals of this research are to (1) understand how hemoglobin released into plasma (pfH) from damaged red blood cells that passage through CPB contributes to organ injury. (2) Determine the amount of pfH necessary to cause organ injury. (3) Determine the concentration changes in protective proteins (called haptoglobin, hemopexin and transferrin) that remove pfH and its degradation products from the circulation. (4) Design a computer-based model that will determine the levels of pfH and protective proteins to predict the potential for organ injury. By studying the dynamics of red blood cell lysis, pfH, protective proteins and organ injury limits will be set for safe levels of pfH following the use of CPB. These results will be compared to existing laboratory-based methods for determining red blood cell damage to predict CPB assist device safety. Further, results from the studies described in this proposal will help develop therapeutic strategies to benefit patients by early detection of pfH and clearance protein levels that occur during CPB.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
No intervention - Biological specimen collection
Time frame: Change from baseline at hour 1 during procedure
Change in Measure hemoglobin released into plasma (pfH), lactate dehydrogenase and iron
Time frame: Change from baseline at hour 2 during procedure
Change in Measure hemoglobin released into plasma (pfH), lactate dehydrogenase and iron
Time frame: Change from baseline at hour 3 during procedure
Change in Measure hemoglobin released into plasma (pfH), lactate dehydrogenase and iron
Time frame: Change from baseline at hour 4 during procedure
Change in Measure hemoglobin released into plasma (pfH), lactate dehydrogenase and iron etc.
Change from Baseline at Hour 1 during procedure
Time frame: Change from baseline at hour 4 post procedure
Change in Measure hemoglobin released into plasma (pfH), lactate dehydrogenase and iron etc.
Change from Baseline at Hour 1 during procedure
Time frame: Change from baseline at hour 2 post procedure
Change in Measure hemoglobin released into plasma (pfH), lactate dehydrogenase and iron etc.
Change from Baseline at Hour 1 during procedure
Time frame: Change from baseline at hour 24 post procedure
Change in Measure hemoglobin released into plasma (pfH), lactate dehydrogenase and iron etc.
Change from Baseline at Hour 1 during procedure
Time frame: Change from baseline on day 2 post procedure
Change in Measure hemoglobin released into plasma (pfH), lactate dehydrogenase and iron etc.
Change from Baseline at Hour 1 during procedure
Time frame: Change from baseline on day 3 post procedure
Change in Measure hemoglobin released into plasma (pfH), lactate dehydrogenase and iron etc.
Change from Baseline at Hour 1 during procedure
Time frame: Change from baseline on day 4 post procedure
Change in Measure hemoglobin released into plasma (pfH), lactate dehydrogenase and iron etc.
Change from Baseline at Hour 1 during procedure
Time frame: Change from baseline on day 5 post procedure
Change in Measure hemoglobin released into plasma (pfH), lactate dehydrogenase and iron etc.
Change from Baseline at Hour 1 during procedure
Time frame: Change from baseline at hour 1 during procedure
Change in creatinine, KIM-1 and NGAL
Time frame: Change from baseline at hour 2 during procedure
Change in creatinine, KIM-1 and NGAL
Time frame: Change from baseline at hour 3 during procedure
Change in creatinine, KIM-1 and NGAL
Time frame: Change from baseline at hour 4 during procedure
Change in creatinine, KIM-1 and NGAL
Time frame: Change from baseline at hour 2 post procedure
Change in creatinine, KIM-1 and NGAL
Time frame: Change from baseline at hour 24 post procedure
Change in creatinine, KIM-1 and NGAL
Time frame: Change from baseline at 2 days post procedure
Change in creatinine, KIM-1 and NGAL
Time frame: Change from baseline at 3 days post procedure
Change in creatinine, KIM-1 and NGAL
Time frame: Change from baseline at 4 days post procedure
Change in creatinine, KIM-1 and NGAL
Time frame: Change from baseline at 5 days post procedure
Change in creatinine, KIM-1 and NGAL
Time frame: Change from baseline at hour 1 during procedure
CBC and red blood cell deformability
Time frame: Change from baseline at hour 2 during procedure
CBC and red blood cell deformability
Time frame: Change from baseline at hour 3 during procedure
CBC and red blood cell deformability
Time frame: Change from baseline at hour 4 during procedure
CBC and red blood cell deformability
Time frame: Change from baseline at hour 2 post procedure
CBC and red blood cell deformability
Time frame: Change from baseline at hour 24 post procedure
CBC and red blood cell deformability
Time frame: Change from baseline at day 2 post procedure
CBC and red blood cell deformability
Time frame: Change from baseline at day 3 post procedure
CBC and red blood cell deformability
Time frame: Change from baseline at day 4 post procedure
CBC and red blood cell deformability
Time frame: Change from baseline at day 5 post procedure
CBC and red blood cell deformability
Time frame: Change from baseline at hour 1 during procedure
Change in hemoglobin clearance measured by plasma haptoglobin and transferrin concentrations
Time frame: Change from baseline at hour 2 during procedure
Change in hemoglobin clearance measured by plasma haptoglobin and transferrin concentrations
Time frame: Change from baseline at hour 3 during procedure
Change in hemoglobin clearance measured by plasma haptoglobin and transferrin concentrations
Time frame: Change from baseline at hour 4 during procedure
Change in hemoglobin clearance measured by plasma haptoglobin and transferrin concentrations
Time frame: Change from baseline at hour 2 post procedure
Change in hemoglobin clearance measured by plasma haptoglobin and transferrin concentrations
Time frame: Change from baseline at hour 24 post procedure
Change in hemoglobin clearance measured by plasma haptoglobin and transferrin concentrations
Time frame: Change from baseline at day 2 post procedure
Change in hemoglobin clearance measured by plasma haptoglobin and transferrin concentrations
Time frame: Change from baseline at day 3 post procedure
Change in hemoglobin clearance measured by plasma haptoglobin and transferrin concentrations
Time frame: Change from baseline at day 4 post procedure
Change in hemoglobin clearance measured by plasma haptoglobin and transferrin concentrations
Time frame: Change from baseline at day 5 post procedure
Change in hemoglobin clearance measured by plasma haptoglobin and transferrin concentrations
Contact information is provided by the study sponsor or research team.
Paul W Buehler, PhD
CONTACT
Tobi Rowden, RN
CONTACT
University of Maryland, Baltimore
Other
Extra-Cellular Hemoglobin, Organ Injury in Extended Cardiopulmonary Bypass
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07549243
Acute Kidney Injury, Cardiac Surgery
Hangzhou, Zhejiang, China
View Trial DetailsNCT04979754
Acute Kidney Injury, Cardiac Surgery
Pessac, France
View Trial DetailsNCT07683299
Cardiac Surgery, Cardiopulmonary Bypass
Medellín, Antioquia, Colombia
View Trial DetailsNCT06702553
Adult Patients Undergoing Cardiovascular Surgery With Cardiopulmonary Bypass, Cardiac Surgery
Boston, Massachusetts, United States
View Trial Details